An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

New findings establish a role for the pro-inflammatory molecule IL-33 in the early development of antibody-producing B cells.

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

New findings from Vanderbilt suggest that blocking the migration of cells involved in asthma may represent a new approach for treating the respiratory condition.

Investigators in the Division of Allergy, Pulmonary, and Critical Care Medicine and the Division of Diabetes, Endocrinology, and Metabolism recently received a $1.25 million grant from the National Institute of Allergy and Infectious Diseases.

Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).